-
公开(公告)号：EP3512557B1
公开(公告)日：2024-09-25
申请号：EP17771393.0
申请日：2017-09-14
IPC分类号： A61K31/704 , A61K31/136 , A61K31/44 , A61K45/06 , A61P35/00 , A61K39/00 , A61K39/395 , A61K31/7032 , A61K31/555 , A61K31/675
CPC分类号： A61K39/0011 , A61K39/39558 , A61K45/06 , A61K31/7032 , A61K31/704 , A61P35/00 , A61K2039/54520130101 , A61K2039/5551620130101 , A61K2039/5557220130101 , A61K39/3955 , C07K16/2818 , A61K2039/50520130101 , C07K2317/7320130101 , A61K31/136 , A61K31/44 , A61K31/555 , A61K31/675 , A61K39/001104 , A61K39/001129 , A61K39/001124 , A61K39/001106 , A61K39/001174 , A61K39/001135
-
公开(公告)号：EP4378531A3
公开(公告)日：2024-09-04
申请号：EP24157422.7
申请日：2018-03-09
IPC分类号： C12N5/02 , C12N5/10 , C12N15/09 , C12N15/11 , C12N15/52 , C12N15/113 , C12P19/34 , C07H21/04 , C12Q1/68 , A61K31/7105 , A61K31/713 , A61K39/00 , A61P35/00 , A61K35/13
CPC分类号： A61K2039/54520130101 , A61K2039/5556120130101 , C12N2320/3220130101 , C12N15/1138 , A61K31/713 , C12N2310/1120130101 , A61P35/00 , A61K2039/58520130101 , A61K39/0011 , A61K31/7105 , A61K39/001103 , A61K2039/515220130101 , A61K35/13
摘要： The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
-
3.发明公开
公开(公告)号：EP4324472A3
公开(公告)日：2024-08-28
申请号：EP23216403.8
申请日：2016-08-05
发明人： Mahr, Andrea , Weinschenk, Toni , Schoor, Oliver , Fritsche, Jens , Singh, Harpreet , Müller, Phillip , Leibold, Julia , Goldfinger, Valentina
IPC分类号： C07K7/06 , C07K14/47 , A61K39/00 , A61P35/00 , C07K14/725 , A61K38/00 , C12N9/64 , C12N5/0783 , C12N5/0784
CPC分类号： C07K14/4748 , C12N2310/1620130101 , A61K38/00 , A61K39/0011 , C07K14/7051 , C07K2319/0020130101 , A61P35/00 , C07K7/06 , A61K39/4611 , C12N5/0639 , C12N5/0636 , A61K39/4644 , C12N9/6445
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumorassociated T-cell peptide epitopes, alone or in combination with other tumorassociated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：EP4192845B1
公开(公告)日：2024-08-28
申请号：EP21763011.0
申请日：2021-07-29
IPC分类号： A61K39/12 , A61K39/00 , C07K14/005 , A61K39/39
-
公开(公告)号：EP4234712B1
公开(公告)日：2024-08-21
申请号：EP23163171.4
申请日：2019-12-19
IPC分类号： C12Q1/6806 , C12N15/10
CPC分类号： C12N15/1075 , C12Q1/6806 , A61K39/0011
-
公开(公告)号：EP4413031A1
公开(公告)日：2024-08-14
申请号：EP22798257.6
申请日：2022-09-28
IPC分类号： C07K14/725 , A61K35/17 , A61K39/00 , C12N9/22 , C12N5/0783 , C12N15/11 , C12N15/90 , C12N15/10
CPC分类号： C12N5/0636 , C12N2510/0020130101 , C12N9/22 , C12N15/102 , C07K14/7051 , C12N2501/230720130101 , C12N2501/231520130101 , C12N15/907 , C12N2310/2020170501 , A61K39/4632 , A61K39/4611 , A61K39/4644 , A61K39/0011
-
公开(公告)号：EP4410376A2
公开(公告)日：2024-08-07
申请号：EP24161083.1
申请日：2016-11-02
发明人： OLIN, Michael
IPC分类号： A61P35/02
CPC分类号： A61K39/39 , C07K7/06 , C07K7/08 , A61K2039/54520130101 , A61K2039/5556120130101 , A61K2039/58520130101 , C07K14/70503 , A61K39/0011 , A61P35/02 , A61K31/203 , A61K31/404 , A61K31/675 , A61K31/7068 , A61K38/2013 , A61K2239/4720230501 , A61K39/4644 , A61K39/4611
摘要： The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behaviour, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.
-
公开(公告)号：EP4402159A1
公开(公告)日：2024-07-24
申请号：EP22868501.2
申请日：2022-09-16
IPC分类号： C07K14/705 , A61K38/20 , A61K39/00 , A61P35/00 , C07K7/06 , C07K14/00 , C12N5/07 , C12N5/078 , C12N5/0783 , C12N5/0784 , C12N15/12 , C12Q1/6809 , G01N33/48 , G01N33/68
CPC分类号： A61P35/00 , C07K14/7051 , C07K14/4748 , A61K39/0011 , A61K39/00 , A61K2039/8220180801 , C07K16/30 , A61K45/06
-
公开(公告)号：EP4400510A2
公开(公告)日：2024-07-17
申请号：EP24158688.2
申请日：2007-07-30
发明人： Weiner, David B. , Yan, Jian
IPC分类号： C07K14/00
CPC分类号： C12N2740/1612220130101 , C12N2740/1613420130101 , C12N2740/1622220130101 , C12N2740/1623420130101 , C12N2740/1632220130101 , C12N2740/1633420130101 , A61K39/12 , A61K2039/52320130101 , A61K2039/5320130101 , C12N2710/2003420130101 , C12N2760/1613420130101 , C12N2770/2423420130101 , A61K38/00 , A61K2039/5420130101 , A61K2039/5553820130101 , A61K2039/58520130101 , C07K14/005 , A61P15/00 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P35/00 , A61P37/04 , A61K39/001157 , A61K39/00 , A61K39/4611 , A61K39/0011 , A61K39/464838
摘要： Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences for HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed. Pharmaceutical composition, recombinant vaccines comprising and live attenuated pathogens are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.
-
公开(公告)号：EP4378531A2
公开(公告)日：2024-06-05
申请号：EP24157422.7
申请日：2018-03-09
IPC分类号： A61P35/00
CPC分类号： A61K2039/54520130101 , A61K2039/5556120130101 , C12N2320/3220130101 , C12N15/1138 , A61K31/713 , C12N2310/1120130101 , A61P35/00 , A61K2039/58520130101 , A61K39/0011 , A61K31/7105 , A61K39/001103 , A61K2039/515220130101
摘要： The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
-
-
-
-
-
-
-
-
-
搜索结果
4510 条记录 (耗时 0.028 秒)
